Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Athira Pharma, Inc. - Common Stock (NQ:ATHA)

4.070 +0.080 (+2.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Athira Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Athira Pharma Announces Reverse Stock Split
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
From Athira Pharma, Inc.
Via GlobeNewswire
Athira (ATHA) Q2 Loss Narrows 74%
Via The Motley Fool
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical... 
From Athira Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 
From Athira Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
From Athira Pharma, Inc.
Via GlobeNewswire
Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
From Athira Pharma, Inc.
Via GlobeNewswire
Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings
 
Via Benzinga
US Stocks Mixed; Trade Gap Widens In July
 
Via Benzinga
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
Athira Pharma stock falls as the company reports mixed results from its Phase 2/3 LIFT-AD clinical trial for Alzheimer's treatment fosgonimeton, with data showing directional improvements but no... 
Via Benzinga
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024
ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
From Athira Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.